INS and type 1 diabetes mellitus: Existing treatment focuses on insulin replacement and has been standard care for over 100 years with only one FDA approved T1D interventional therapy known as teplizumab, an anti-CD3 antibody that results in the exhaustion of CD8+ T cells (Herold et al., 2023).